Eckert & Ziegler stock holds after first-half revenue tops $149 million
Published on 08/13/2026 at 13:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eckert & Ziegler SE (ISIN DE0005659700) reported first-half 2026 revenue of 149.3 million euros and adjusted EBIT of 33.3 million euros on August 13, 2026, giving investors a fresh read on the German radiopharma and isotope group.
The company also said net income rose to 22.4 million euros, or 0.36 euros per share, while medical segment adjusted EBIT increased 7 percent to 24.9 million euros. The broader group's adjusted EBIT fell 6 percent, but revenue excluding extraordinary license income was up 4 percent and the result improved 9 percent on that basis.
Half-year numbers set the tone
The half-year update shows a mixed picture: revenue in the first six months reached 149.3 million euros, while adjusted EBIT still came in at 33.3 million euros. The comparison matters because the company said the adjusted figures were helped by stripping out extraordinary license income in the prior-year period, which left revenue 4 percent higher and the result 9 percent better on that basis.
Net income at 22.4 million euros was stronger than the 21.4 million euros reported a year earlier, and EPS improved to 0.36 euros from 0.34 euros. That gives the market a simple read on profitability even as the group-wide adjusted EBIT slipped 6 percent year over year.
Calendar pressure on the shares
The stock entered the session with the latest SDAX line showing 13.75 euros, down 1.36 percent on August 12, 2026, after trading between 13.73 and 13.89 euros. The same market table showed a 1-year change of -27.37 percent, which keeps valuation pressure visible even after the half-year update.
For context, the company is scheduled for Q2 figures on August 13, 2026, and the fresh half-year release gives the market a clean benchmark against that calendar point. The medical segment's 7 percent EBIT increase is the clearest positive detail in the update, while the 6 percent decline in group adjusted EBIT is the main offset.
Medical segment stands out
The product and business mix still leans on medical and isotope-related activities, with the medical segment's adjusted EBIT of 24.9 million euros highlighting where operating strength is coming from. That is the piece investors will likely compare most closely with the groupwide margin picture after August 13, 2026.
As a business line, medical radioisotopes and related radiopharma applications remain central to the company's operating profile, and the latest figures keep that segment in the spotlight for margin and mix analysis.
Share level to watch
The stock was quoted at 13.75 euros on August 12, 2026, after the market close snapshot in the SDAX table, with the 1-year performance still down 27.37 percent. The latest half-year report gives that price a new earnings backdrop, but the share still needs a stronger profit trend to change the longer-term chart.
More on Eckert & Ziegler
Investor relations update for the first half of 2026.
Company Eckert & Ziegler SE, ISIN DE0005659700, Ticker: ETG, Exchange: Regulierter Markt in Frankfurt, Sector: Health Care, Industry: Health Care Equipment & Supplies, Index membership: SDAX and TecDAX.
